ArticleThe lancet. HIV2019

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.

Andrew N Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.